Search clinical trials for: ABT-652 12 mg - 18 mg

Total 334 results

AbbVie (prior sponsor, Abbott)

Terminated

A Study Comparing the Efficacy and Safety of ABT-652 to Placebo in Subjects With Diabetic Neuropathic Pain

Diabetic Neuropathic Pain

United States
Watson Pharmaceuticals

Completed

Safety and Efficacy of an Anticholinergic Agent for Treatment of Primary Axillary Hyperhidrosis

Hyperhidrosis

United States
Abbott

Completed

Study to Evaluate the Role of Itopride HCI in Patients With Irritable Bowel Syndrome With Predominant Constipation

Irritable Bowel Syndrome

Pakistan
Tobira Therapeutics, Inc.

Completed

A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients

HIV-1 Infection
RemeGen Co., Ltd.

Recruiting

A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome

Primary Sjogren's Syndrome

China
AbbVie (prior sponsor, Abbott)
Genentech, Inc.

Completed

Study of ABT-869 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer (NSCLC)

United States, Canada, France, Singapore, Taiwan
Yale University
National Institute of Mental Health (NIMH); University of Pennsylvania; Columbia... and other collaborators

Recruiting

A Translational and Neurocomputational Evaluation of a Dopamine Receptor 1 Partial Agonist for Schizophrenia

Early Course Schizophrenia Spectrum Disorder

United States
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-389949

Healthy Subjects

Netherlands
University of Aarhus
Aarhus University Hospital

Completed

Does the Bioactive Substance in Coffee, Cafestol, Have Preventive Properties on Type-2-diabetes? (Acute Substudy)

Obesity, Abdominal

Denmark
Boehringer Ingelheim

Completed

Efficacy and Safety of Talsaclidine in Patients With Mild to Moderate Dementia of Alzheimer Type

Alzheimer Disease
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Assess the Tolerability, Safety, Pharmacodynamics, and Pharmacokinetics of Ascending Single Doses (Including Food Interaction) and Ascending Multiple Doses of ACT-453859, and Multiple Doses of Setipiprant (ACT-129968)

Healthy
Gangnam Severance Hospital

Completed

Remimazolam Bolus for General Anesthesia

Loss of Consciousness

Korea, Republic of
Repros Therapeutics Inc.

Completed

Safety, Pharmacokinetics and Efficacy of Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Premenopausal Women With Uterine Fibroids Who Have Completed ZPV-200

Uterine Fibroids
Sunovion

Completed

Dasotraline SEP360-105 Pediatric PK/PD Study

Pediatric Attention Deficit Hyperactivity Disorder

United States
Repros Therapeutics Inc.

Completed

Comparison of Two Formulations of Proellex for Oral Administration

Healthy

United States
Idorsia Pharmaceuticals Ltd.

Completed

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-451840 in Healthy Subjects (Part A)

Healthy

France
MedImmune LLC

Completed

Safety/Efficacy of MEDI-551 in Combination With Immunomodulating Therapies in Subjects With Aggressive B-cell Lymphomas

Relapsed/Refractory Aggressive B-cell Lymphomas

United States
Mitsubishi Tanabe Pharma Corporation

Completed

Efficacy and Safety of Increased Dose of TA-650(Infliximab) in Patients With Rheumatoid Arthritis

Rheumatoid Arthritis
Boryung Pharmaceutical Co., Ltd

Completed

Efficacy, Safety and Pharmacodynamic/Pharmacokinetic Study of Fimasartan (BR-A-657•K) (Fimasartan)

Essential Hypertension
GlaxoSmithKline

Completed

A Double-blind, Escalating Dose, Randomized, Placebo-controlled Study Assessing PK, Safety, Tolerability in Non-ambulant DMD Subjects (DEMAND I)

Muscular Dystrophies

France, United States
Repros Therapeutics Inc.

Completed

Extension of Study ZPV-200

Uterine Fibroids

United States
Taiho Pharmaceutical Co., Ltd.

Completed

A Phase 2 Study of TAS-303 in Female Patients With Stress Urinary Incontinence

Stress Urinary Incontinence

Japan
Columbia University
National Institute on Aging (NIA)

Active, not recruiting

Dietary Modulation of Neuroinflammation in Age-Related Memory Disorders

Inflammation | Memory Loss

United States
Medicines for Malaria Venture
Richmond Pharmacology Limited

Completed

Determine the Tolerability and Safety of Atovaquone-proguanil (ATV-PG) Co-administered With Amodiaquine (AQ)

Malaria

United Kingdom
Otonomy, Inc.

Completed

OTO-104 for Meniere's Disease

Meniere's Disease

United States
Idorsia Pharmaceuticals Ltd.

Terminated

A Study in Healthy Subjects to Investigate the Safety and Tolerability of ACT- 541478 as Well as What ACT-541478 Does to the Body and the Way the Body Takes up, Distributes, and Gets Rid of ACT-541478

Healthy

Germany
GTx

Withdrawn

Add-on Study for Protocol G200802 (NCT02463032): Effect of GTx-024 on Maximal Neuromuscular Function and Lean Body Mass

ER+ and AR+ Breast Cancer

United States
Serpin Pharma, LLC
University of Virginia

Recruiting

SP16 as a Therapeutic for COVID-19 Induced ARDS

Pneumonia | SARS CoV 2 Infection

United States
Bio Genuine (Shanghai) Biotech Co., Ltd.

Recruiting

Efficacy and Safety of BG2109 in Chinese Subjects With Endometriosis

Endometriosis | Moderate to Severe Endometriosis-associated Pain

China
Idorsia Pharmaceuticals Ltd.

Completed

A Study to Evaluate the Pharmacokinetics of ACT-541468 in Subjects With Mild, Moderate, and Severe Hepatic Impairment

Hepatic Impairment

Switzerland
University of Texas Southwestern Medical Center
GlaxoSmithKline

Recruiting

Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis

AL Amyloidosis | Amyloidosis

United States
Idorsia Pharmaceuticals Ltd.

Completed

Clinical Study to Assess the Pharmacokinetics, Safety, and Tolerability of ACT-129968 in Healthy Subjects

Healthy Subjects

Germany
Fundacion Clinic per a la Recerca Biomédica

Unknown

Efficacy of GZR/EBR in Early Chronic Hepatitis C in HIV/HCV Co-infected Patients (EARLY-HEP-C)

Hepatitis C | HIV

Spain
Merck Sharp & Dohme LLC

Terminated

A Study of the Safety, Tolerance, and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children (P03579)

Fungal Infections
Ain Shams University

Completed

Doubling the Iron Dose to Prevent IDA in Twin Pregnant Women (IDA)

Hematologic Pregnancy Complications

Egypt
Estetra

Completed

E4/DRSP Single and Multiple Dose PK and Early QT Study

Contraception
Ardea Biosciences, Inc.

Completed

RDEA3170 PK/PD Study

Gout

United States
Serum Institute of India Pvt. Ltd.
PPD

Completed

Safety Study of Dengushield in Healthy Adults

Dengue | Phase 1

Australia
Idorsia Pharmaceuticals Ltd.

Completed

A Medical Research Study to Evaluate the Effects of ACT-246475 in Adults With Heart Attack

Acute Myocardial Infarction

Switzerland, Israel, Belgium
Chengdu PLA General Hospital

Unknown

Qingkailing Injection Versus Puerarin Injection on Withdrawal Rate of Corticosteroids in Patients With Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
VTBIO Co. LTD
ADM Korea Inc

Completed

Study to Explore the Optimal Dosage/Administration in Alzheimer's Disease (ADD)

Alzheimer's Disease

Korea, Republic of
Idorsia Pharmaceuticals Ltd.
Janssen Biotech, Inc.

Completed

A Research Study to Show the Effect of Aprocitentan in the Treatment of Difficult to Control (Resistant) High Blood Pressure (Hypertension) and Find Out More About Its Safety (PRECISION)

Resistant Hypertension

Spain, Israel, Czechia, United States, Canada, China, Hungary, Netherlands, Poland, United Kingdom, Germany, Australia, Belgium, Finland, France, Greece, Italy, Lithuania, Russian Federation, Ukraine
Janssen Research & Development, LLC

Completed

A Study of the Histone Deacetylase Inhibitor (HDACi) Quisinostat (JNJ-26481585) in Patients With Previously Treated Stage Ib-IVa Cutaneous T-cell Lymphoma

Lymphoma, T-Cell, Cutaneous

France, United Kingdom, Spain, Portugal, United States, Germany
Idorsia Pharmaceuticals Ltd.

Completed

Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ACT-389949 in Healthy Subjects

Healthy Subjects

United Kingdom
Insud Pharma

Terminated

Ivermectin to Prevent SARS-CoV-2 (COVID-19) Hospitalisation in Subjects Over 50

COVID-19 | SARS-CoV-2

Spain
Idorsia Pharmaceuticals Ltd.

Completed

Clazosentan in Preventing the Occurrence of Cerebral Vasospasm Following an Aneurysmal Subarachnoid Hemorrhage (aSAH) (CONSCIOUS-1)

Aneurysmal Subarachnoid Hemorrhage

United States, Canada
Supernus Pharmaceuticals, Inc.

Completed

Treatment of Impulsive Aggression in Subjects With ADHD in Conjunction With Standard ADHD Treatment (CHIME 2)

Attention Deficit Hyperactivity Disorder (ADHD)

United States
Idorsia Pharmaceuticals Ltd.

Completed

Single-ascending Dose Study to Investigate the Tolerability, Safety, Pharmacokinetics, and Pharmacodynamics of ACT-462206

Pharmacokinetics | Pharmacodynamics | Tolerability | Safety

Netherlands
Pfizer

Withdrawn

Multiple-Dose Safety Study Of RN316 For TheTreatment Of Hypercholesterolemia

Dyslipidemia | Hypercholesterolemia
Taiwan Liposome Company

Completed

Phase IIa, Randomized, Double Blinded, Placebo Controlled, Dose Finding Study for TLC599 in OA Patients

Osteoarthritis of the Knee

Taiwan, Australia

3

Subscribe